TABLE 4.
Dalbavancin tissue concentrations (safety population)
| Tissue | Dalbavancin concn (mean [SD]; no. of samples) at hours (days) postdose that samples were collected: |
|||||
|---|---|---|---|---|---|---|
| 12 (0.5) | 24 (1) | 72 (3) | 168 (7) | 240 (10) | 336 (14) | |
| Plasma (μg/ml)a | 85.3 (18.9); 31 | NDb | ND | ND | ND | 15.3 (4.1); 31 |
| Synovium (μg/g)c | 25.0 (0); 3 | 17.9 (7.8); 3 | 19.5 (4.9); 3 | 19.2 (8.9); 4 | 25.0 (0); 2 | 15.9 (7.9); 3 |
| Synovial fluid (μg/ml)c | 22.9; 1 | 27.4 (10.8); 4 | 19.2 (4.9); 3 | 11.6 (3.3); 2 | 13.9 (1.0); 3 | 6.2 (1.7); 2 |
| Bone (μg/g) | 6.3 (3.1); 5 | 5.0 (3.5); 5 | 4.6 (3.8); 5 | 3.8 (2.7); 5 | 3.7 (2.2); 5 | 4.1 (1.6); 5 |
| Skin (μg/g)c | 19.4 (7.9); 2 | 12.5 (6.5); 3 | 13.8 (1.4); 2 | 15.7 (1.0); 2 | 21.6; 1 | 13.8 (2.1); 2 |
a
Mean (SD) plasma concentrations in 31 subjects at 772 and 1,080 h were 6.2 (2.4) and 3.4 (1.7), respectively.
b
ND, not detected.
c
Concentrations above the upper limit of quantification are reported as 25 μg/unit.